Matthew Autterson graduated in the year of 1980, with a degree in finance at the Michigan State University. He was also a part of the University of Denver Tax program. And as a subsidiary of Fiserv, his career started at the First Trust Corporation. Matthew Autterson left that company in the year of 1982 and he joined a smaller team, and in this team, he aspired to start a new Colorado state charter trust company. This new company would be related to a company, New York-based financial services company Integrated Resources.
Autterson became the president of the Resources Trust Company in the year of 1986. Then in the year of 1989, the Resources Trust Company and their assets that were initially owned by Integrated Resources, in were obtained by Broad, Inc. Broad, Inc became what is known as SunAmerica, which was obtained by Aig for $18 billion in the year of 1998.
Resource Trust Company was obtained by Fiserve from AIG in May of 2001, and after this sale was finished, they became one of the biggest and most successful state- chartered, FDIC-insured depository trust companies in the U.S. This company employed 700 people, it provided services to over 200,000 customers, and obtained over 15,000 independent financial advisors who were registered. And with this company’s massive success, this company had over $20 billion in custodial assets, and more than $1 billion in deposits. Click Here for more information
Autterson also takes part in the Board of Directors of Falci Adaptive Biosystems, also known as FAB. FAB also assisted him in his interest in philanthropy. For several years Matthew Autterson has been a leader of board of the following, which reveals his interest in philanthropy: he is on the Board of the Denver Zoo, and at the Denver Zoological Foundation, also at the the Webb-Waring Foundation, and is also a Chairman of the Board of Directors at the Denver Hospice. Lastly, he is formerly the president and chief executive officer, and a board member of a company, CNS Bioscience, Inc. This company was created in the year of 2013, and it serves as a clinical drug development company, which centers around neuropathic pain.
More on: https://angel.co/matthew-autterson